Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow vTv Therapeutics Inc.

Get SEC filing alerts via email and in your feed for vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral treatments for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin, targets type 1 diabetes by improving glycemic control and reducing hypoglycemia risk. The company focuses on innovative mechanisms, strategic collaborations, and international trials to bring first-in-class therapies to market, addressing significant unmet medical needs in diabetes and chronic inflammatory conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from vTv Therapeutics Inc.

1
1
vTv Therapeutics Inc. vTv Therapeutics Reports $36.8M Revenue and $24.1M Net Income in Latest Quarter

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
vTv Therapeutics Inc. vTv Therapeutics Reports $26.97 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
vTv Therapeutics Inc. vTv Therapeutics Reports $0 Revenue and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
vTv Therapeutics Inc. vTv Therapeutics Reports $6M Net Loss and Zero Revenue for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
vTv Therapeutics Inc. vTv Therapeutics Reports $5.1 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
vTv Therapeutics Inc. vTv Therapeutics Reports $1.0 Million Revenue and $18.5 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
vTv Therapeutics Inc. vTv Therapeutics Reports Improved Liquidity and Reduced Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments